Vincerx Pharma, Inc. (VINC)
Total Valuation
Vincerx Pharma has a market cap or net worth of $13.69 million. The enterprise value is -$4.55 million.
| Market Cap | 13.69M |
| Enterprise Value | -4.55M |
Important Dates
The last earnings date was Tuesday, November 14, 2023, before market open.
| Earnings Date | Nov 14, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
Vincerx Pharma has 21.38 million shares outstanding. The number of shares has increased by 1.24% in one year.
| Shares Outstanding | 21.38M |
| Shares Change (YoY) | +1.24% |
| Shares Change (QoQ) | +0.33% |
| Owned by Insiders (%) | 25.96% |
| Owned by Institutions (%) | 60.47% |
| Float | 17.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.86 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.18.
| Current Ratio | 2.58 |
| Quick Ratio | 2.48 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -160.10% and return on invested capital (ROIC) is -283.69%.
| Return on Equity (ROE) | -160.10% |
| Return on Assets (ROA) | -116.10% |
| Return on Capital (ROIC) | -283.69% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.19M |
| Employee Count | 41 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -1.91% in the last 52 weeks. The beta is 0.04, so Vincerx Pharma's price volatility has been lower than the market average.
| Beta (1Y) | 0.04 |
| 52-Week Price Change | -1.91% |
| 50-Day Moving Average | 0.91 |
| 200-Day Moving Average | 1.12 |
| Relative Strength Index (RSI) | 34.62 |
| Average Volume (30 Days) | 50,847 |
Short Selling Information
The latest short interest is 128,670, so 0.60% of the outstanding shares have been sold short.
| Short Interest | 128,670 |
| Short Previous Month | 130,378 |
| Short % of Shares Out | 0.60% |
| Short % of Float | 0.73% |
| Short Ratio (days to cover) | 3.23 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -52.50M |
| Pretax Income | -48.85M |
| Net Income | -48.85M |
| EBITDA | -47.95M |
| EBIT | -48.85M |
| Earnings Per Share (EPS) | -$2.31 |
Balance Sheet
The company has $20.87 million in cash and $2.77 million in debt, giving a net cash position of $18.11 million or $0.85 per share.
| Cash & Cash Equivalents | 20.87M |
| Total Debt | 2.77M |
| Net Cash | 18.11M |
| Net Cash Per Share | $0.85 |
| Equity / Book Value | 15.74M |
| Book Value Per Share | 0.74 |
| Working Capital | 13.97M |
Cash Flow
| Operating Cash Flow | -46.25M |
| Capital Expenditures | n/a |
| Free Cash Flow | -46.25M |
| FCF Per Share | -$2.17 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vincerx Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -360.32% |
| FCF Yield | -341.15% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.24% |
| Shareholder Yield | -1.24% |
Analyst Forecast
The average price target for Vincerx Pharma is $4.00, which is 524.81% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.00 |
| Price Target Difference | 524.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -32.73% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |